TITLE

The Industry

PUB. DATE
October 2007
SOURCE
Pharmaceutical Representative;Oct2007, Vol. 37 Issue 10, p10
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers news briefs related to pharmaceutical industry. Merck & Co. Inc. has agreed to acquire San Diego-based NovaCardia Inc. Cell Therapeutics Inc. is buying U.S. marketing, sales and development rights to Biogen Idec's Zevalin. Watson Pharmaceuticals Inc. and Depomed Inc. have announced a copromotion agreement for Depomed's ProQuin XR, an extended-release treatment for uncomplicated urinary tract infections.
ACCESSION #
26947392

 

Related Articles

  • Watson takes its top five place in generics.  // Australian Journal of Pharmacy;Mar2012, Vol. 93 Issue 1102, p50 

    The article reports on the acquisition of Ascent Pharmahealth Ltd. by Watson Pharmaceuticals Inc. which has helped the company in acquiring the fifth largest position among the generic pharmaceutical companies in Australia.

  • Update.  // Medical Marketing & Media;May2004, Vol. 39 Issue 5, p15 

    Reports on developments in the United States pharmaceutical industry as of May 2004. Food and Drug Administration (FDA) has called on 10 antidepressant manufacturers to change their labeling; Mylan Laboratories has filed suit against Procter and Gamble and Watson Pharmaceuticals; FDA approved a...

  • Merck sets science in motion. Arnold, Matthew // Medical Marketing & Media;Jan2008, Vol. 43 Issue 1, p40 

    The article provides information about Merck & Co. Inc., a pharmaceutical company which won the "Medical Marketing and Media's (MM&M)" Company of the Year Award in 2007. According to some officials, the key to Merck's transformation was an organizational shake-up which brought the scientific and...

  • Watson to Expand Global Footprint With Arrow Acquisition.  // Chain Drug Review;7/20/2009, Vol. 31 Issue 12, p112 

    The article reports on the move of Watson Pharmaceuticals Inc. to acquire the Arrow Group for 1.75 billion dollars in cash and stock. It mentions that the deal is expected to help the generic drug manufacturer to expand globally in the market as well as boost earnings in 2010. Watson president...

  • REPORTER'S NOTEBOOK.  // Drug Store News;11/20/2006, Vol. 28 Issue 16, p22 

    The article offers news briefs related to the pharmaceutical industry in the U.S. IMS Health Inc. revealed that sales of drugs in retail pharmacy has increased by about 6 percent between August 2005 and August 2006. The Federal Trade Commission has approved the proposal of Watson Pharmaceuticals...

  • Watson Pharma snaps up Sekhsaria Chem.  // Chemical Business;May2006, Vol. 20 Issue 5, p72 

    Reports on the acquisition of Sekhsaria Chemicals based in Mumbai, India by Watson Pharmaceuticals. Services provided by Sekhsaria Chemicals to the global pharmaceutical industry; Details of the operations of Sekhsaria Chemicals including its financial performance; Plan of Watson to establish a...

  • Cardiovascular News Round-up.  // PharmaWatch: Monthly Review;Oct2007, Vol. 6 Issue 10, p10 

    The article offers news briefs related to the pharmaceutical industry. Merck & Co. Inc. has completed the acquisition of NovaCardia Inc., a privately held clinical-stage pharmaceutical company focused on cardiovascular disease. Meanwhile, Sanofi Aventis SA has announced that one-year findings...

  • The Buyside: April Proved a Warm Month for Pharma M&A. Noto, Anthony // Mergers & Acquisitions Report;8/5/2013, Vol. 26 Issue 31, p1 

    The article reports on financial services firm Burrill & Co.'s data which showed an increase in merger and acquisition (M&A) activity for the pharmaceutical sector in April 2013. Some of the largest deals included Nestle SA for Pfizer Inc.'s nutrition business, Actavis Group and Watson...

  • Elan Divests Hypertension Drug to Watson.  // Chemical Market Reporter;9/2/2002, Vol. 262 Issue 7, p8 

    Reports the granting of rights to Watson Pharmaceuticals Inc. by the Elan Corp. PLC on the exclusive U.S. rights to nifedipine ER, the generic version of Bayer's hypertension drug. Implementation of asset divestiture program; Aims of the company for cash infusion; Consent settlement of the sale...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics